Epigenetic Strategies to Boost Cancer Immunotherapies

Recently, immunotherapeutic approaches have shown impressive responses in a subset of cancer patients. However, the rate of success is low and a large percentage of treated patients do not experience clinical benefits. Therefore, additional strategies are needed to improve responses and select respo...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2017-05, Vol.18 (6), p.1108
Main Author: Barrero, Maria J
Format: Article
Language:English
Subjects:
cancer
Cancer immunotherapy
Cancer therapies
DNA methylation
Drugs
Epigenesis, Genetic - genetics
Epigenetics
Humans
Immunosuppressive agents
Immunotherapy
Immunotherapy - methods
Kinases
Neoplasms - genetics
Neoplasms - therapy
Patients
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recently, immunotherapeutic approaches have shown impressive responses in a subset of cancer patients. However, the rate of success is low and a large percentage of treated patients do not experience clinical benefits. Therefore, additional strategies are needed to improve responses and select responsive patients. Emerging data suggest that epigenetic drugs can improve the responses to immunotherapy. Understanding the mechanisms of resistance to immunotherapy and the epigenetic events that take place during immune evasion is critical to providing a rational combined use of immunotherapies and epigenetic drugs. This review focuses in the epigenetic mechanisms involved in the responses to immunotherapy and how current drugs that target epigenetic regulators impact on them.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms18061108